STATUTORY RULES
1966 No. 144
________
REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1966.*
I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1966.
Dated this twentieth day of October, 1966.
CASEY
Governor-General.
By His Excellency’s Command,
(Signed) A. G. Forbes
Minister of State for Health.
________
Amendments of the National Health (Pharmaceutical Benefits) Regulations†
Commencement.
1. These Regulations shall come into operation on the first day of November, 1966.
First Schedule.
2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—
(a) by omitting the words—
“ Botulinum Antitoxin.”;
(b) by omitting the words—
“ Dichloralphenazone Tablets.”;
(c) by omitting the words—
“ Guanethidine Sulphate.”;
(d) by inserting after the words—
“ Chloroquine Phosphate.”
the words—
“ Chloroquine Phosphate Injection.”;
______________________________________________________________________
* Notified in the Commonwealth Gazette on , 1966.
† Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152; and 1966, No. 80.
10467/66.—Price 25c (2s. 6d.) 9/13.10.1966
(e) by inserting after the words—
“ Magnesium Stearate.”
the words—
“ Maize Oil.”;
(f) by omitting the word—
“ Mannitol.”;
(g) by inserting after the word—
“ Picrotoxin.”
the words—
“ Picrotoxin Injection.”;
(h) by inserting after the words—
“ Rabies Vaccine.”
the word—
“ Santonin.”; and
(i) by omitting the words—
“ Trifluoperazine Hydrochloride.”.
Second and Third Schedules.
3. The Second and Third Schedules to the National Health (Pharmaceutical Benefits) Regulations are repealed and the following Schedules inserted in their stead:—
SECOND SCHEDULE Regulation 10 (3.).
Allowable Compounds (if any) of Certain Drugs or Medicinal Preparations
Pharmaceutical Benefits | Allowable Compounds (if any) |
Acrylic Resin................... | __ |
Aluminium Powder, B.P.C........... | Aluminium Powder B.P.C. with Liquid Paraffin B.P. and Zinc Oxide Ointment B.P. |
Aluminium Sodium Silicate.......... | Aluminium Sodium Silicate with Belladonna |
Amphotericin B.................. | Tetracycline with a buffering agent and Amphotericin B. |
Aneurine Hydrochloride, B.P......... | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Antazoline Sulphate............... | Antazoline Sulphate with Naphazoline Nitrate B.P. |
Ascorbic Acid, B.P................ | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Attapulgite..................... | Dihydrostreptomycin Sulphate B.P. 1958 with Attapulgite, Pectin and Hydrated Alumina Powder B.P. |
Bacitracin, B.P.................. | Polymyxin B Sulphate B.P. with Bacitracin B.P. and Neomycin Sulphate B.P. |
Betamethasone Disodium Phosphate.... | — |
Betamethasone Phosphate........... | — |
Brompheniramine Maleate .......... | — |
Calciferol...................... | — |
Calcium Lactobionate.............. | Thenalidine with Calcium Lactobionate |
Carbachol, B.P.................. | — |
Carbinoxamine Maleate............ | — |
Carbromal, B.P.................. | Carbromal B.P., with Pentobarbitone Sodium B.P. |
Chloramine, B.P.C................ | — |
Chloramphenicol, B.P.............. | Chloramphenicol B.P. with Polymyxin B. Sulphate B.P. |
Second Schedule—continued
Pharmaceutical Benefits | Allowable Compounds (if any) |
Chlorhexidine Gluconate .............. | — |
Chlorpheniramine Maleate, B.P.......... | — |
Chlorpromazine Hydrochloride, B.P....... | — |
Chlortetracycline Hydrochloride, B.P...... | — |
Clemizole Tannate................... | — |
Cortisone Acetate, B.P................ | — |
Cymogran........................ | — |
Cyproheptadine Hydrochloride.......... | — |
Cyclizine Hydrochloride, B.P........... | Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P. |
Demecarium Bromide................ | — |
Demethylchlortetracycline Hydrochloride, B | Demethylchlortetracycline Hydrochloride B.P. with Nystatin B.P. |
Dexchlorpheniramine Maleate........... | — |
Dextran.......................... | Dextran with Dextrose B.P. |
| Dextran in Normal Saline |
Dicyclomine Hydrochloride, B.P.C........ | — |
Dienoestrol, B.P.................... | — |
Digoxin, B.P...................... | — |
Dihydrostreptomycin Sulphate, B.P. 1958... | Dihydrostreptomycin Sulphate B.P. 1958 with Attapulgite, Pectin and Hydrated Alumina Powder B.P. |
| Dihydrostreptomycin Sulphate B.P. 1958 with Kaolin, Pectin and Aluminium Hydroxide Gel |
Dihydrotachysterol.................. | — |
Dimethicone....................... | — |
Diphenhydramine Hydrochloride, B.P...... | Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P. |
Diphenylpyraline Hydrochloride......... | — |
Diphtheria Vaccine, B.P............... | Diphtheria and Tetanus Vaccine B.P. |
| Diphtheria, Tetanus and Pertussis Vaccine B.P. |
Dyflos, B.P.C...................... | — |
Ecothiopate Iodide................... | — |
Entsufon......................... | Hexachlorophane B.P. with Entsufon |
Ergometrine Maleate................. | Oxytocin with Ergometrine Maleate |
Ergotamine Tartrate, B.P.............. | Ergotamine Tartrate B.P. with Caffeine B.P. |
| Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P. |
| Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P. |
| Ergotamine Tartrate B.P. with Caffeine B.P. and Meclozine Hydrochloride B.P. |
Erythromycin Oral Suspensions and Syrups | — |
Erythromycin Paediatric Drops........... | — |
Ethosuximide...................... | — |
Ferric Hydroxide.................... | — |
Ferrous Aminoacetosulphate............ | — |
Ferrous Succinate................... | — |
Framycetin Sulphate................. | — |
Fusidic Acid (Diethanolamine Salt) | — |
Galactomin....................... | — |
Glucose Indicator................... | — |
Glyceryl Guaiacolate................. | Theophylline with Glyceryl Guaiacolate |
Gramicidin........................ | Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin |
Second Schedule—continued
Pharmaceutical Benefits | Allowable Compounds (if any) |
Hamamelis Dry Extract, B.P.C........... | Hamamelis Dry Extract B.P.C. with Zinc Oxide B.P. |
Hexachlorophane, B.P................ | Hexachlorophane B.P. with Entsufon |
| Hexachlorophane B.P. with Lissapol |
| Hexachlorophane B.P. in Soap Solution |
Hydrocortisone, B.P.................. | — |
Hydrocortisone Acetate, B.P............ | Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P. |
Idoxuridine....................... | — |
Ipecacuanha, B.P.................... | Phenolphthalein B.P. with Aloin B.P.C., Dry Extract of Belladonna B.P., Strychnine B.P.C. 1959 and Ipecacuanha B.P. |
Isoprenaline Hydrochloride............. | — |
Kanamycin Sulphate, B.P.C............ | — |
Levallorphan Tartrate, B.P............. | Levallorphan Tartrate B.P. with Pethidine Hydrochloride B.P. |
Lissapol......................... | Lissapol with Spearmint Oil B.P.C. and Cetrimide B.P. |
| Hexachlorophane B.P. with Lissapol |
Lofenalac........................ | — |
Magnesium Chloride................. | Ammonium Chloride B.P. with Sodium Chloride B.P., Potassium Chloride B.P. and Magnesium Chloride |
| Sodium Lactate with Potassium Chloride B.P., Magnesium Chloride and Sodium Chloride B.P. |
Mebhydrolin Napadisylate, B.P.C......... | — |
Meclozine Hydrochloride, B.P........... | Ergotamine Tartrate B.P. with Caffeine B.P. and Meclozine Hydrochloride B.P. |
Mepyramine Maleate, B.P.............. | — |
Methacycline...................... | — |
Methdilazine Hydrochloride............ | — |
Methenamine Mandelate............... | — |
Methyl Glucamine................... | Theophylline B.P. with Methyl Glucamine |
Minafen......................... | — |
Morphine Tartrate................... | Morphine Tartrate with Tacrine |
Naphazoline Nitrate, B.P.............. | Naphazoline Nitrate B.P. with Antazoline Sulphate |
Neomycin Sulphate, B.P............... | Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P. |
| Polymyxin B. Sulphate B. P. with Bacitracin B.P. and Neomycin Sulphate B.P. |
| Neomycin Sulphate B.P. with Kaolin B.P. |
| Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin |
Neostigmine Methylsulphate, B.P......... | — |
Neutramigen...................... | — |
Nicotinamide, B.P................... | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Nitrofurantoin, B.P.................. | — |
Nortriptyline Hydrochloride............ | — |
Nystatin, B.P...................... | Tetracycline with a buffering agent and Nystatin B.P. |
| Oxytetracycline Hydrochloride B.P. with a buffering agent and Nystatin B.P. |
| Demethylchlortetracycline Hydrochloride B.P. with Nystatin B.P. |
Oxytetracycline Hydrochloride, B.P....... | Oxytetracycline Hydrochloride B.P. with Polymyxin B. Sulphate B.P. |
| Oxytetracycline Hydrochloride B.P. with a buffering agent and Nystatin B.P. |
Oxytocin......................... | Oxytocin with Ergometrine Maleate |
Second Schedule—continued
Pharmaceutical Benefits | Allowable Compounds (if any) |
Pancreatin Enzyme, U.S.N.F. XI......... | — |
Papaveretum, B.P.C.................. | Papaveretum B.P.C. with Hyoscine Hydrobromide B.P. |
Penicillin, Benethamine, B.P.C.......... | Penicillin, Benethamine B.P.C. with Procaine Penicillin B.P. and Sodium Penicillin B.P. |
Penicillin, Benzathine, B.P............. | Penicillin, Benzathine B.P. with Procaine Penicillin B.P. and Potassium Penicillin B.P. |
Penicillin, Benzyl, B.P................. | Penicillin, Benzyl B.P. with Streptomycin Sulphate B.P. |
| Fortified Procaine Penicillin Injection B.P. |
| Penicillin, Benzyl B.P. with Procaine Penicillin B.P. and Streptomycin Sulphate B.P. |
Penicillin, Phenoxymethyl (Benzathine, Calcium, Hydrabamine or Potassium Salt or Free Acid) | — |
Penicillin, Potassium, B.P.............. | Penicillin, Benzathine B.P. with Procaine Penicillin B.P. and Potassium Penicillin B.P. |
Penicillin, Procaine, B.P............... | Penicillin, Benzathine B.P. with Procaine Penicillin B.P. and Potassium Penicillin B.P. |
| Fortified Procaine Penicillin Injection B.P. |
| Penicillin, Benethamine B.P.C. with Procaine Pencillin B.P. and Sodium Penicillin B.P. |
| Penicillin, Benzyl B.P. with Procaine Penicillin B.P. and Streptomycin Sulphate B.P. |
Penicillin, Sodium, B.P............... | Penicillin, Benethamine B.P. with Procaine Penicillin B.P. and Sodium Penicillin B.P. |
Pentolinium Tartrate, B.P.............. | Pentolinium Tartrate B.P. with Ephedrine Hydrochloride B.P. |
Pertussis Vaccine, B.P................ | Diphtheria, Tetanus and Pertussis Vaccine B.P. |
Pethidine Hydrochloride, B.P........... | Pethidine Hydrochloride B.P. with Levallorphan Tartrate B.P. |
| Pethidine Hydrochloride B.P. with Scopolamine Hydrobromide B.P. |
Phenethicillin Potassium............... | — |
Pheniramine Maleate................. | — |
Phenytoin........................ | — |
Pilocarpine Hydrochloride............. | — |
Pipenzolate Methobromide............. | — |
Pituitary (Posterior Lobe), Powdered, B.P.C. | — |
Polymyxin B. Sulphate, B.P............ | Chloramphenicol B.P. with Polymyxin B. Sulphate B.P. |
| Oxytetracycline Hydrochloride B.P. with Polymyxin B. Sulphate B.P. |
| Polymyxin B. Sulphate B.P. with Bacitracin B.P. and Neomycin Sulphate B.P. |
| Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin |
| Polymyxin B. Sulphate B.P. with Propylene Glycol and Acetic acid |
Methylprednisolone, B.P.............. | — |
Prednisolone Sodium Hemisulphate....... | — |
Prednisolone Sodium Phosphate, B.P.C..... | — |
Prednisolone Trimethylacetate, B.P........ | — |
Promethazine Hydrochloride, B.P......... | — |
Riboflavine, B.P.................... | Vitamin A with Anuerine Hydrochloride B.P. Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D. |
Senna Fruit, B.P.................... | — |
Silver Nitrate, Toughened, B. P.......... | — |
Sobee........................... | — |
Second Schedule—continued
Pharmaceutical Benefits | Allowable Compounds (if any) |
Sodium Lactate..................... | Sodium Lactate with Potassium Chloride B.P. and Sodium Chloride B.P. |
| Sodium Lactate with Potassium Chloride B.P., Magnesium Chloride and Sodium Chloride B.P. |
| Sodium Lactate with Sodium Chloride B.P. and Dextrose B.P. |
| Sodium Lactate with Sodium Chloride B.P. |
| Sodium Lactate with Potassium Chloride B.P. and Dextrose B.P. |
Sodium Potassium Tartrate, B.P.C......... | Compound Effervescent Powder B.P.C. |
Sodium Tauroglycocholate, B.P.C. 1954.... | Sodium Tauroglycocholate B.P.C. 1954 with Cascara Dry Extract B.P. |
Spearmint Oil, B.P.C................. | Lissapol with Spearmint Oil B.P.C. and Cetrimide B.P. |
Strychnine, B.P.C. 1959............... | Phenolphthalein with Aloin, Dry Extract of Belladonna, Strychnine B.P.C. 1959 and Ipecacuanha |
Sulphacetamide, B.P.C................ | Sulphacetamide B.P.C. with Sulphamerazine B.P. 1958 and Sulphadiazine B.P. |
Sulphafurazole, B.P.................. | — |
Sulphamerazine, B.P. 1958............. | Sulphamerazine B.P. 1958 with Sulphadiazine B.P. and Sulphathiazole B.P.C. |
| Sulphamerazine B.P. 1958 with Sulphadiazine B.P. and Sulphacetamide B.P.C. |
| Sulphamerazine B.P. 1958 with Sulphadiazine B.P. and Sulphadimidine B.P. |
Sulphamethoxazole.................. | — |
Sulphaphenazole, B.P.C............... | — |
Sulphathiazole, B.P.C................ | Sulphathiazole B.P.C. with Sulphamerazine B.P. 1958 and Sulphadiazine B.P. |
Surgical Cement.................... | — |
Surgical Cement Solvent............... | — |
Tacrine.......................... | Morphine Sulphate B.P. with Tacrine |
| Morphine Tartrate with Tacrine |
Tetanus Vaccine, B.P................. | Diphtheria and Tetanus Vaccine B.P. |
| Diphtheria, Tetanus and Pertussis Vaccine B.P. |
Tetracycline....................... | Tetracycline with a buffering agent |
| Tetracycline with a buffering agent and Amphotericin B. |
| Tetracycline with a buffering agent and Nystatin B.P. |
Thenalidine....................... | Thenalidine with Calcium Lactobionate |
Thenalidine Tartrate.................. | Thenalidine Tartrate with Calcium Lactate B.P. and Calcium Gluconate B.P. |
Theobromine, B.P.C................. | Theobromine B.P.C. with Phenobarbitone B.P. |
Thioridazine....................... | — |
Tragacanth, Indian (Gum Karaya)......... | — |
Trifluoperazine Hydrochloride........... | — |
Trimeprazine Tartrate, B.P.C............ | — |
Triprolidine Hydrochloride, B.P.C........ | — |
Vasopressin....................... | — |
Velactin......................... | — |
Viomycin Pantothenate............... | Viomycin Sulphate B.P. with Viomycin Pantothenate |
Viomycin Sulphate, B.P | Viomycin Sulphate B.P. with Viomycin Pantothenate |
Viprynium Embonate................. | — |
Vitamin A........................ | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Vitamin D........................ | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
|
|
THIRD SCHEDULE Regulation 11.
Drugs and Medicinal Preparations Additional to the Drugs and Medicinal Preparations in the British Pharmacopoeia
Cajuput Spirit, B.P. 1948. | |
Acetohexamide. | Calamine Cream Oily, A.P.F. |
Acidified Golden Syrup, A.P.F. 1955. | Calcium Aurothiomalate. |
Acriflavine, B.P.C. | Calcium Di-Oxytetracycline. |
Acrylic Resin. | Calcium Gluconogalactogluconate. |
Adrenaline Hydrochloride. | Calcium Lactobionate. |
Adrenaline Mucate. | Calcium Phosphate, B.P.C. |
Agar, B.P.C. 1954. | Calumba, Concentrated Infusion, B.P. 1948. |
Aldosterone. | Calumba Tincture, B.P. 1948. |
Alkavervir. | Capsicum Ointment, B.P.C. |
Allopurinol. | Capsicum Tincture, B.P.C. |
Aloin, B.P.C. | Carbamazepine. |
Almond Oil Volatile Bitter, B.P.C. 1959. | Carbarsone, B.P.C. |
Aloxidone. | Carbinoxamine Maleate. |
Aluminium Acetate Solution, B.P.C. | Cardamom Aromatic Tincture, B.P.C. |
Aluminium Hydroxide Mixture, A.P.F. | Catechu Tincture, B.P.C. |
Aluminium Sodium Polyhydroxy Monocarbonate Hexitol Complex. | Cephaloridine. |
Cetomacrogol Emulsifying Wax, B.P.C. | |
Aluminium Sodium Silicate. | Cetyl Alcohol Compound. |
Aluminium Powder, B.P.C. | Chloramine, B.P.C. |
Amaranth Solution, A.P.F. | Chloramphenicol Palmitate, B.P.C. |
Amaranth Solution, Compound, A.P.F. | Chloramphenicol Stearate. |
Amaranth Solution, B.P.C. | Chloramphenicol Succinate. |
Aminocaproic Acid. | Chlorazanil Hydrochloride. |
Amitriptyline Hydrochloride | Chlorhexidine Diacetate. |
Ammonia Aromatic Spirit, B.P.C. | Chlorhexidine Gluconate. |
Ammonia Solution Strong, B.P.C. | Chlorobenzol Disulphonamide. |
Ammonium Bicarbonate, B.P.C. | Chlorotrianisene, B.P.C. |
Ammonium Bromide, B.P.C. | Chlorthalidone, B.P.C. |
Amphotericin B. | Cholera El Tor Combined Vaccine. |
Angiotensin Amide. | Choline Theophyllinate, B.P.C. |
Antazoline Methanesulphonate, B.P.C. | Cinnamon Spirit, B.P.C. 1949. |
Antazoline Sulphate. | Cinnamon Water, Concentrated, B.P.C. |
Attapulgite. | Clemizole Hydrochloride. |
Aurothioglucose. | Clemizole Tannate. |
Azathioprine. | Clopamide. |
Beclamide. | Clove Concentrated Infusion, B.P.C. 1954. |
Beeswax, Yellow, B.P.C. | Coal Tar, B.P.C. |
Belladonna Suppository, B.P. 1948. | Cochineal Tincture, B.P. 1948. |
Benedict’s Solution, A.P.F. | Coconut Oil, B.P.C. 1949. |
Benzalkonium Chloride. | Codeine, B.P.C. 1954. |
Benzoin, B.P.C. | Copper Sulphate, B.P.C. |
Benzoinated Lard, B.P.C. 1954. | Creosote, B.P.C. 1959. |
Benzoin Compound Tincture, B.P.C. | Cudbear Tincture, A.P.F. 1947. |
Benzoin Tincture, B.P.C. | Curd Soap, B.P.C. |
Benzylpenicillin in Oil. | Cyclopenthiazide. |
Bephenium Hydroxynaphthoate, B.P.C. | Cyclothiazide. |
Betamethasone Disodium Phosphate. | Cycrimine Hydrochloride. |
Betamethasone Phosphate. | Cymogran. |
Bethanidine Sulphate. | Cyproheptadine Hydrochloride. |
Biperiden Hydrochloride. | Death Adder Antivenene. |
Bismuth Subgallate, B.P.C. | Demecarium Bromide. |
Bretylium Tosylate. | Deoxycortone Glucoside. |
Brompheniramine Maleate. | Desferrioxamine. |
Brown Snake Antivenene. | Deslanoside. |
Buchu Concentrated Infusion, B.P.C. 1954. | Dexamethasone Sodium Phosphate. |
Butabarbital Sodium. | Dexchlorpheniramine Maleate. |
Butyl Aminobenzoate, B.P. 1953. | Dextran. |
Cade Oil, B.P.C. | Dextriferron. |
Caffeine and Sodium Benzoate, B.P.C. 1954. | Diazepam. |
Caffeine Citrate, B.P.C. 1959. |
|
Third Schedule—continued
Dicyclomine Hydrochloride, B.P.C. | Hydroxybenzoate Compound Powder, A.P.F. |
Digitalis Tincture, B.P.C. 1959. | Hydroxyprogesterone Caproate. |
Dihydroergotamine Methanesulphonate. | Hyoscine Methobromide. |
Dihydromorphinone Hydrochloride, B.P.C. 1949. | Hypophosphorous Acid, Dilute, B.P.C. |
Dihydrostreptomycin Sulphate, B.P. 1958. | Idoxuridine. |
Dihydrotachysterol. | Indomethacin. |
Dimethicone, B.P.C. | Insulin Injection, specially purified. |
Dimethindene Maleate. | Insulin Injection, Biphasic. |
Diphenylpyraline Hydrochloride. | Insulin Injection, Neutral. |
Dipyridamole. | Insulin Isophane Injection, specially purified. |
Disodium Stilboestrol Diphosphate. | Insulin Injection, Special P (Pig). |
Dithiazine Iodide. | Iodochlorhydroxyquinoline. |
Dyflos, B.P.C. | Iodoform, B.P.C. 1954. |
Ecothiopate Iodide. | Iron Aminoates. |
Entsufon. | Iron Dextran. |
Ephedrine, B.P.C. | Iron Oxide Saccharated. |
Ergot, Liquid Extract, B.P. 1914. | Iron Polymaltose Complex. |
Erythrityl Tetranitrate. | Iron Sorbitol Complex. |
Erythromycin Ethyl Succinate. | Isoprenaline Hydrochloride. |
Erythromycin Glucoheptonate. | Isopropamide Iodide. |
Erythromycin Lactobionate. | Isothipendyl Hydrochloride, B.P.C. |
Erythromycin Stearate. | Kanamycin Sulphate, B.P.C. |
Ethacrynic Acid. | Kitasamycin. |
Ethanolamine, B.P.C. | Lanatoside-C. |
Ethanolamine Oleate. | Lavender Spike Oil, B.P.C. |
Ether Nitrous Spirit, B.P.C. 1959. | Lemon Tincture, B.P. 1958. |
Ethionamide. | Lincomycin Hydrochloride. |
Ethoxzolamide. | Lipopancreatin. |
Ethylidene Dicoumarin. | Lissapol. |
Ethylnoradrenaline Hydrochloride. | Lobelia Ethereal Tincture, B.P.C. |
Ethyloestrenol | Lofenalac. |
Eucalyptol, B.P.C. | Lypressin. |
Extract of Ox Bile, B.P. 1948. | Magenta, B.P.C. |
Ferric Hydroxide. | Magnesium-Aluminium Hydroxide. |
Ferrous Aminoacetosulphate. | Magnesium Chloride. |
Ferrous Carbonate Saccharated, B.P.C. 1959. | Magnesium Hydroxide, B.P.C. |
Ferrous Phosphate Compound Syrup, B.P.C. | Mebhydrolin Napadisylate, B.P.C. |
Ferrous Phosphate with Quinine and Strychnine Syrup, B.P.C. | Medroxyprogesterone Acetate. |
Ferrous Succinate. | Melphalan. |
Fluorouracil Sodium. | Mepenzolate Bromide. |
Folinic Acid. | Mercaptomerin Sodium. |
Framycetin Sulphate. | Mercuric Chloride, B.P.C. |
Frusemide. | Mestanolone. |
Fusidic Acid, Diethanolamine Salt. | Metaraminol Bitartrate. |
Galactomin. | Metformin Hydrochloride. |
Gall and Opium Ointment, B.P.C. | Methacycline. |
Gelsemium Tincture, B.P.C. | Methazolamide. |
Glucagon Hydrochloride. | Methdilazine Hydrochloride. |
Glucose Indicator. | Methenamine Mandelate. |
Glycerophosphate Compound Syrup, A.P.F. | Methenolone Acetate. |
Glyceryl Guaiacolate. | Methotrexate. |
Glycopyrronium Bromide. | Methoxamine Hydrochloride, B.P.C. |
Glymidine. | Methsuximide. |
Goats Milk, dehydrated. | Methyclothiazide. |
Gramicidin. | Methyl Glucamine. |
Hamamelis Dry Extract, B.P.C. | Methylphenobarbitone, B.P.C. |
Hamamelis Liquid Extract, B.P.C. | Methylprednisolone Acetate. |
Heparin Retard. | Metyrapone. |
Hexocyclium Methylsulphate. | Minafen. |
Honey, Purified, B.P.C. | Morphine Tartrate. |
Hydrargaphen. | Myrrh Gum, Powdered, B.P.C. |
Hydrocyanic Acid, Dilute, B.P.C. 1954. |
|
Third Schedule—continued
Myrrh Tincture, B.P.C. | Potable Water. |
Nalidixic Acid. | Potassium Chlorate, B.P.C. |
Nandrolone Decanoate. | Potassium, Effervescent Tablets. |
Natamycin. | Prednisolone Sodium Hemisuccinate. |
Neutramigen. | Prednisolone Sodium Hemisulphate. |
Niclosamide. | Prednisolone Sodium Phosphate, B.P.C. |
Nicotinyl Alcohol Tartrate. | Prednisolone Tertiary Butyl Acetate. |
Nicoumalone. | Propranolol Hydrochloride. |
Nitromin. | Protoveratrine A. |
Nortriptyline Hydrochloride. | Pumilio Pine Oil, B.P.C. |
Nux Vomica, Dry Extract, B.P.C. | Pyrazinamide. |
Oestradiol Dipropionate, B.P.C. 1954. | Pyridine Aldoxime Methiodide. |
Oestrone, B.P.C. 1954. | Quillaia Tincture, B.P.C. |
Oily Ophthalmic Vehicle, A.P.F. 1955. | Quinethazone. |
Orange Peel Compound, Concentrated Infusion, B.P.C. 1954. | Raspberry Syrup, B.P.C. |
Orange Peel, Concentrated Infusion, B.P.C. | Rauwolfia Alkaloids. |
Orciprenaline Sulphate. | Red Back Spider Antivenene. |
Oxycodone Pectinate. | Rolitetracycline. |
Oxymel, B.P.C. | Rosemary Oil, B.P.C. |
Oxymel of Squill, B.P.C. | Salicylamide. |
Oxymesterone. | Senega, Concentrated Infusion, B.P.C. |
Oxyphencyclimine Hydrochloride. | Senna Compound Mixture, B.P.C. 1959. |
Oxyphenonium Bromide. | Senna, Concentrated Infusion, B.P.C. 1959. |
Oxytetracycline. | Senna Fruit Extract (Standardised). |
Oxytocin. | Siberian Fir Oil, B.P.C. 1949. |
Pancreatin Enzyme, U.S.N.F. XI. | Silver Protein, B.P.C. |
Papaveretum, B.P.C. | Silver Protein Mild, B.P.C. |
Papuan Black Snake Antivenene. | Sobee. |
Para-Aminosalicylic Acid. | Sodium Carbonate Anhydrous, B.P.C. |
Paraben Ophthalmic Phosphate Buffer, A.P.F. 1955. | Sodium Edetate, B.P.C. |
Paraben Ophthalmic Vehicle, A.P.F. 1955. | Sodium Folate. |
Paraffin Liquid Light, B.P.C. | Sodium Lactate. |
Paramethasone Acetate. | Sodium Nitrite, B.P.C. |
Pargyline Hydrochloride. | Sodium Potassium Tartrate, B.P.C. |
Pectin. | Sodium Tauroglycocholate, B.P.C. 1954. |
d-Penicillamine Hydrochloride, B.P.C. | Spearmint Oil, B.P.C. |
Penicillinase. | Spiramycin. |
Penicillin, Benethamine, B.P.C. | Squill Tincture, B.P.C. |
Pentaerythritol Tetranitrate, diluted, B.P.C. | Stanolone. |
Penthienate Methobromide. | Stanozolol. |
Peru Balsam, B.P.C. | Stearic Acid, B.P.C. |
Phenazone, B.P.C. | Storax, Prepared, B.P.C. |
Phenazopyridine Hydrochloride. | Strophanthus Tincture, B.P. 1948. |
Phenethicillin Potassium. | Strychnine, B.P.C. 1959. |
Phenformin Hydrochloride. | Sulphacetamide, B.P.C. |
Pheniramine Maleate. | Sulphadiazine Sodium, B.P.C. |
Pheniramine Para-Aminosalicylate. | Sulphadimethoxine, B.P.C. |
Phenol Ointment, B.P. 1948. | Sulphaguanidine, B.P.C. |
Phenoxymethylpenicillin, Benzathine. | Sulphamerazine, B.P. 1958. |
Phenoxymethylpenicillin, Hydrabamine. | Sulphamethoxazole. |
Phensuximide. | Sulphamethoxydiazine. |
Phenthimentonium. | Sulphaphenazole, B.P.C. |
Phenytoin. | Sulphasalazine. |
Phthalylsulphacetamide. | Sulphathiazole, B.P.C. |
Physostigmine, B.P.C. | Sulphinpyrazone, B.P.C. |
Pilocarpine Hydrochloride. | Sulphomyxin Sodium. |
Pipenzolate Methobromide. | Sulphurated Potash, B.P.C. |
Pituitary (Posterior Lobe) Powdered, B.P.C. | Sulphuric Acid, Dilute, B.P.C. |
Polyoestradiol Phosphate. | Sulphur Sublimed, B.P.C. |
Polythiazide. | Sultiame. |
| Surgical Cement. |
Third Schedule—continued
Surgical Cement Solvent. | Trasylol. |
Sustanon. | Tretamine. |
Syrup Glucose Liquid, B.P.C. | Triamcinolone, B.P.C. |
Tacrine. | Triamterene. |
Taipan Antivenene. | Tricyclamol Chloride. |
Tar Ointment, B.P.C. 1959. | Tridihexethyl Chloride. |
Tartrazine, B.P.C. 1954. | Triethanolamine, B.P.C. |
Testosterone Oenanthate. | Trimeprazine Tartrate, B.P.C. |
Tetanus Immune Globulin (Human). | Trinitrophenol, B.P.C. 1959. |
Tetracycline. | Triprolidine Hydrochloride, B.P.C. |
Thenalidine. | Trolnitrate Phosphate. |
Thenalidine Tartrate. | Vadrine. |
Theobromine, B.P.C. | Valerian Ammoniated Tincture, B.P.C. |
Theobromine and Sodium Salicylate, B.P. 1953. | Vanillin. |
Theophylline Ethanoate of Piperazine. | Vasopressin Tannate. |
Thiethylperazine. | Velactin. |
Thioridazine. | Vinblastine Sulphate. |
Thiotepa. | Vincristine Sulphate. |
Thyrotrophin. | Vinegar of Squill, B.P.C. |
Tiger Snake Antivenene. | Viomycin Pantothenate. |
Titanium Dioxide, B.P.C. | Viprynium Embonate. |
Tolu Tincture, B.P.C. 1959. | Vitamin A. |
Tragacanth, Indian (Gum Karaya). | Vitamin D. |
Fourth Schedule.
4. The Fourth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by inserting after the words—
“ Citronella Oil, B.P.C.”
the words—
“ Maize Oil, B.P.”.
Fifth Schedule.
5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule inserted in its stead:—
__________
FIFTH SCHEDULE Regulation 14.
Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Acetylsalicylic Acid Tablets, B.P................. |
|
Soluble Acetylsalicylic Acid Tablets B.P. | |
Compound Acetylsalicylic Acid Tablets, A.P.F. | Any disease or condition in a pensioner |
Compound Acetylsalicylic Acid Tablets, B.P.C. | |
Soluble Compound Acetylsalicylic Acid Tablets | |
Acrylic Resin............................... | |
Ileostomy or colostomy conditions | |
Aldosterone................................ | With the written authority of the Director-General, treatment of an acute crisis in— |
Addison’s disease | |
Salt-losing congenital adrenal hypoplasia | |
Allopurinol................................ |
|
Aminocaproic Acid.......................... |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Amitriptyline Hydrochloride............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride, Imipramine Hydrochloride or Nortriptyline Hydrochloride |
Amphetamine Sulphate Tablets, B.P........ | Any disease or condition in a pensioner |
Amphotericin B..................... | Systemic fungal infection |
Ampicillin Capsules, B.P................ |
|
Ampicillin Injections.................. | |
Ampicillin Tablets.................... | |
Aneurine Hydrochloride Tablets, B.P........ | Any disease or condition in a pensioner |
Angiotensin Amide................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| |
Ascorbic Acid Tablets, B.P.............. | Any disease or condition in a pensioner |
Azathioprine....................... |
|
Beclamide......................... | |
Betamethasone Tablets................. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets except cerebral tumors and cerebral oedema |
| |
| |
| |
Betamethasone Disodium Phosphate Injection. | Intra-articular use |
Busulphan Tablets, B.P................ | Leukaemia |
|
|
Calciferol Tablets, B.P................. | With the written authority of the Director-General— |
Calciferol, B.P...................... | Hypoparathyroidism |
| Chronic hypoparathyroid tetany |
| Vitamin D-resistant rickets |
Calcium Aminosalicylate............... | Tuberculosis |
Calcium Gluconogalactogluconate Effervescent Tablets | Hypoparathyroidism |
Carbamazepine...................... | Epilepsy |
| Trigeminal neuralgia |
Cephaloridine....................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Chlorambucil Tablets, B.P.............. | Malignant lymphoma and related conditions |
Chloramine Deodorant Tablets and Powder... | Ileostomy or colostomy conditions |
Chloramphenicol Capsules, B.P........... | Bacterial meningitis |
| Haemophilus influenzae infections |
| Intra-ocular infections |
| Rickettsial infections |
| Salmonella septicaemia |
| Typhoid and paratyphoid |
| Other serious infections sensitive only to Chloramphenicol |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | |
Chloramphenicol Injections.............. |
| |
Chloramphenicol Tablets............... | ||
Chloramphenicol Oral Suspension......... | ||
Chlorotrianisene Tablets................ | Carcinoma of the prostate | |
Chlorpromazine Hydrochloride........... | Any disease or condition of a pensioner | |
| Any disease or condition in a patient receiving treatment in or at an approved hospital | |
| With the written authority of the Director-General— | |
| Late-stage malignancy | |
| Radiation sickness | |
| Huntington’s chorea | |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital. | |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride, Imipramine Hydrochloride, or Nortriptyline Hydrochloride | |
Chlortetracycline Capsules, B.P........... | Brucellosis | |
| Herpes zoster ophthalmicus | |
| Intestinal amoebiasis | |
| Leptospirosis | |
| Lymphogranuloma venereum | |
| Psittacosis | |
| Rickettsial infections | |
| Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins | |
| Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur | |
Chlortetracycline Hydrochloride Granules.... | A disease or condition specified in this column in relation to Chlortetracycline Capsules | |
Choline Theophyllinate................ |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
Cloxacillin Sodium, B.P................ | ||
Cloxacillin Capsules, B.P............... | ||
Compound Codeine Tablets, B.P.......... |
| Any disease or condition in a pensioner |
Compound Codeine Soluble Tablets, B.P..... | ||
Codeine Phosphate with Acetylsalicylic Acid Soluble Tablets | ||
Codeine Phosphate with Acetylsalicylic Acid Tablets | ||
Codeine Phosphate with Acetylsalicylic Acid and Phenacetin Tablets | ||
Codeine Phosphate with Acetylsalicylic Acid, Phenacetin and Caffeine Tablets | ||
Cod Liver Oil Emulsion................ | Any disease or condition in a child under the age of twelve years or in a pensioner | |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | |
|
| With the written authority of the Director-General— |
Corticotrophin Injection, B.P........... | A disease or condition specified in this column in relation to Cortisone Injection | |
Corticotrophin Gelatin Injection, B.P. | ||
| Hypsarrhythmia | |
Corticotrophin Zinc Hydroxide Injection, B.P. | Salaam convulsions | |
| The prevention of side effects of corticosteroid therapy | |
Cortisone Injection, B.P. | With the written authority of the Director-General— | |
| Anaemia, acquired haemolytic | |
| Addison’s disease | |
| Adrenocortical hypoplasia | |
| Adrenalectomy, total | |
| Adrenogenital syndrome | |
| Agranulocytosis | |
| Behcet’s syndrome | |
| Cranial arteritis | |
| Cushing’s syndrome, including hyperadrenocorticalism | |
| Dermatitis, acute exfoliative | |
| Dermatomyositis | |
| Encephalomyelitis | |
| Encephalomyelitis, acute disseminated | |
| Guillain-Barré syndrome | |
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis | |
| Hansen’s disease | |
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry | |
| Hodgkin’s disease | |
| Idiopathic hypercalcaemia | |
| Inflammatory conditions of the uveal tract and retina | |
| Keratoplasty | |
| Leucine-sensitive hypoglycaemia | |
| Leukaemia | |
| Lymphosarcoma and follicular lymphoma | |
| Metastatic breast cancer | |
| Mycosis fungoides | |
| Nephrosis or nephrotic syndrome | |
| Neuromyelitis optica | |
| Optic neuritis following removal of tumor of the brain | |
| Panhypopituitarism | |
| Pemphigus | |
| Periarteritis nodosa | |
| Progressive transverse myelitis | |
| Pseudohermaphroditism | |
| Purpura, Henoch’s | |
| Purpura, thrombocytopenic | |
| Regional ileitis (Crohn’s disease) | |
| Recticulum cell sarcoma | |
| Rheumatic carditis, acute | |
| Sarcoidosis | |
| Scleroderma | |
| Severe reactions of the skin and mucosa following X-ray therapy | |
| Splenic neutropenia | |
| Status asthmaticus | |
| Steroid therapy prior to operation in patients under steroid therapy | |
| Stevens-Johnson syndrome | |
| Still’s disease in a child under the age of sixteen years | |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | ||
Cortisone Injection, B.P.—continued | Sympathetic ophthalmitis | ||
| Systemic lupus erythematosus | ||
| Temporal arteritis | ||
| Tropical and non-tropical spine and all forms of malabsorption associated with those diseases | ||
| Type II Nephritis | ||
| Ulcerative colitis proven by sigmoidscopy or radiological report | ||
Cortisone Tablets, B.P............. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection | ||
|
| Established megalocytic anaemia | |
Cyanocobalamin Injection, B.P....... |
| Neuroblastoma | |
|
| Subacute combined degeneration of the cord | |
Cymogran..................... | With the written authority of the Director-General, phenylketonuria | ||
Cycloserine, B.P................. |
| Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Cycloserine Capsules, B.P........... | |||
Demethylchlortetracycline Capsules, B.P. |
| ||
Demethylchlortetracycline Hydrochloride Oral Paediatric Drops and Oral Suspension | A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus | ||
Demethylchlortetracycline Hydrochloride with Nystatin | Any disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin | ||
Deodorant Detergent Solution (Lissapol with Spearmint Oil and Cetrimide) | Ileostomy or colostomy conditions | ||
Deoxycortone Aqueous Injections |
| ||
Deoxycortone Acetate Injection, B.P. |
| ||
Deoxycortone Trimethylacetate Injection, B.P. |
| Addison’s disease | |
Deoxycortone Acetate Implants, B.P. |
| Adrenalectomy, total | |
Deoxycortone Acetate Tablets........ |
|
| |
Desferrioxamine................. | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Dexamethasone Tablets, B.P......... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets except cerebral tumors and cerebral oedema | ||
Dexamethasone Sodium Phosphate Injections | Intra-articular use | ||
Dexamphetamine Tablets, B.P........ | Any disease or condition in a pensioner | ||
Diazepam..................... | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Dienoestrol Cream............... | Any disease or condition in a pensioner | ||
Dienoestrol Tablets, B.P........... | Carcinoma of the prostate | ||
| Mammary carcinoma | ||
| Any disease or condition in a pensioner | ||
Dihydrostreptomycin Sulphate Injection | As an alternative to Streptomycin Sulphate in the case of a person who is being treated for a disease or condition specified in this column in relation to Streptomycin Sulphate and who is allergic to Streptomycin Sulphate | ||
Dihydrotachysterol............... | Parathyroid deficiency | ||
Diloxanide Furoate Tablets, B.P...... | Amoebic dysentery | ||
Dimethicone................... | Ileostomy or colostomy conditions | ||
Disodium Stilboestrol Diphosphate | Carcinoma of the prostate | ||
Dithiazanine Iodide............... | Infestations of Trichuris trichiura or Strongyloides stercoralis | ||
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | ||
Ditophal...................... | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Erythromycin................... | Mycoplasma pneumoniae (Eaton’s Agent). | ||
| Staphylococcol septicaemia or staphylococcol pneumonia. | ||
| A disease or condition specified in this column in relation to Chlortetracycline Capsules—except herpes zoster ophthalmicus | ||
Ethinyloestradiol Tablets, B.P........ | Any disease or condition in a pensioner | ||
| Hereditary telangiectasis | ||
| Pre-menopausal castration syndrome | ||
| Turner’s syndrome | ||
Ethionamide.................... | Tuberculosis | ||
Ethisterone Tablets, B.P............ | Turner’s syndrome | ||
Ethyloestrenol.................. | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | ||
Fludrocortisone Tablets, B.P.......... | Addison’s disease | ||
| Adrenocortical hypoplasia | ||
| Total adrenalectomy | ||
Fluorouracil Sodium.............. | Carcinoma of the colon and rectum | ||
Fluoxymesterone Tablets, B.P........ | Castration syndrome (male) | ||
| Mammary carcinoma | ||
|
| ||
Folic Acid Injection............... |
| Macrocytic anaemia | |
Folic Acid Tablets, B.P............ |
| Sprue or the sprue-like syndrome | |
Folinic Acid.................... | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Framycetin Sulphate Tablets......... | Bowel sterilization preparatory to major surgery | ||
Fusidic Acid (Sodium Salt or Diethanolamine Salt) | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic | ||
Galactomin.................... | With the written authority of the Director-General, galactosaemia | ||
Goats Milk, dehydrated............ | With the written authority of the Director-General, cows milk allergy in children under the age of four years | ||
Griseofulvin Tablets, B.P............ | With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination | ||
Halibut Liver Oil Capsules.......... |
| ||
Hexachlorophane with Entsufon....... |
| Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Hexachlorophane with Lissapol....... | |||
Hexachlorophane in Soap Solution |
| ||
Hydrocortisone Injection........... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection | ||
Hydrocortisone Acetate Injection, B.P. | Intra-articular use | ||
Hydrocortisone Sodium Succinate Injection | Acute adrenal failure due to medical or surgical crises | ||
| Stevens-Johnson syndrome | ||
Hydrocortisone Sodium Succinate Soluble Tablet | With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report | ||
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | ||
|
| Established megalocytic anaemia | |
Hydroxocobalamin Injection, B.P | Neuroblastoma | ||
| Sub-acute combined degeneration of the cord | ||
| Habitual abortion | ||
Hydroxyprogesterone Caproate...... | Progesterone deficiency proven by hormonal assay of lateral wall smear | ||
| |||
Idoxuridine.................... | Infections caused by Herpes Simplex Virus | ||
Imipramine Tablets, B.P............ | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital | ||
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride, Imipramine Hydrochloride or Nortriptyline Hydrochloride | ||
Isoniazid Tablets, B.P............. | Tuberculosis | ||
Kanamycin Sulphate.............. | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic | ||
Kitasamycin................... | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Levorphanol Tartrate.............. | Obstetrical use | ||
| Severe intractable pain | ||
Lincomycin Hydrochloride.......... | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Liothyronine Tablets, B.P........... | Myxoedema | ||
| Myxoedema coma | ||
Lipopancreatin.................. | Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Lofenalac...................... | With the written authority of the Director-General, phenylketonuria | ||
Medroxyprogesterone Acetate Tablets.. | Endometrial carcinoma | ||
Medroxyprogesterone Acetate Injections | Endometrial carcinoma | ||
Habitual abortion | |||
| Progesterone deficiency proven by hormonal assay of lateral wall smear | ||
Melphalan..................... | Malignant melanoma | ||
| Multiple myeloma | ||
Mercaptopurine Tablets, B.P......... | Allergic angiitis | ||
| Leukaemia | ||
| Lupus erythematosus | ||
| Periarteritis | ||
Mestanolone.................... | Mammary carcinoma | ||
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | ||
Methacycline……………………………. | A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus | ||
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whoso treatment it may be prescribed) for supply under Part VII. of the Act | |||
|
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | ||
Methenolone Acetate............. | ||||
Methicillin Sodium............... |
| Any disease or condition in a patient receiving treatment in or at an approved hospital | ||
Methicillin Injection, B.P........... | ||||
Methotrexate Tablets ............. | Leukaemia and neoplastic disease | |||
Methotrexate Injections ............ | Any disease or condition in a patient receiving treatment in or at an approved hospital | |||
Methylamphetamine Injection,B.P. |
| Any disease or condition in a pensioner | ||
Methylamphetamine Tablets, B.P. | ||||
Metyrapone.................... | Any disease or condition in a patient receiving treatment in or at an approved hospital | |||
Minafen ...................... | With the written authority of the Director-General, phenylketonuria | |||
Morphine Sulphate, B.P. with Tacrine Tablets | Severe intractable pain | |||
Mustine Hydrochloride Injection ..... | Malignant lymphoma and related conditions | |||
Nalidixic Acid.................. | With the written authority of the Director-General, urinary tract infections | |||
Nandrolone Phenylpropionate Injection, B.P. |
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | ||
Nandrolone Decanoate............ | ||||
Neomycin Tablets, B.P............. | Bowel sterilization preparatory to major surgery | |||
| Portal-systematic encephalopathy | |||
Neutramigen................... | With the written authority of the Director-General— | |||
| Cows milk allergy in children under the age of four years | |||
| Galactosaemia | |||
| Lactose intolerance | |||
| Fibrocystic disease of the pancreas in children under the age of four years | |||
Nicotinic Acid Tablets, B.P.......... | Any disease or condition in a pensioner | |||
Nitrofurantoin Tablets, B.P.......... |
| Urinary tract infections | ||
Nitrofurantoin Oral Suspension .. | ||||
Nitromin...................... | Malignant lymphoma and related conditions | |||
Nortriptyline Hydrochloride......... | Any disease or condition in a patient receiving treatment in or at an approved hospital | |||
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital | |||
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thiordazine Hydrochloride, Amitriptyline Hydrochloride, Imipramine Hydrochloride or Nortriptyline Hydrochloride | |||
Nystatin Tablets, B.P.............. |
| Monilia infections | ||
Orciprenaline Sulphate Injection |
|
| ||
Orciprenaline Sulphate Solution for Inhalation | Any disease or condition in a patient receiving treatment in or at an approved hospital | |||
Oxycodone Pectinate.............. | Late-stage malignancy | |||
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | |
Oxymesterone............... | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | |
Oxytetracycline Hydrochloride Capsules |
| |
Oxytetracycline Tablets, B.P...... |
| A disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus |
Oxytetracycline Injections....... | ||
Calcium di-Oxytetracycline Oral Suspension | ||
Calcium di-Oxytetracycline Paediatric Drops |
|
|
|
| |
| A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus | |
Pancreatin, B.P............... | Fibrocystic disease | |
Pancreatin Enzyme U.S.N.F. XI... | Pancreatico-duodenectomy | |
Pancreatic steatorrhoea | ||
| Tuberculosis | |
Paracetamol Suspension........ | Any disease or condition in a pensioner | |
Paracetamol Tablets, B.P........ | ||
Paramethasone Acetate......... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection | |
Paraffin Liquid Emulsion........ |
| |
Paraffin Liquid Emulsion with Phenolphthalein | ||
Pargyline Hydrochloride........ | Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Penicillamine............... | With the written authority of the Director-General— | |
| Cystinosis | |
| Cystinuria with calculus formation | |
|
| |
Penicillin Benzathine Tablets and Capsules | Prevention of recurrent streptococcal infections, including rheumatic fever | |
Penicillin Benzyl Tablets, B.P..... | ||
Penicillin Benzyl Capsules....... | ||
Benzylpenicillin with Streptomycin Sulphate |
| |
Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate | Endocarditis due to Streptococcus faecalis or Streptococcus viridans | |
Pethidine Hydrochloride with Levallorphan Tartrate | Obstetrical use | |
Phenacetin with Codeine Phosphate and Pentobarbitone Sodium | Any disease or condition in a pensioner | |
Phytomenadione Injection, B.P.... | Antidote to anticoagulants | |
Pituitary, Posterior Lobe, Insufflation | Diabetes insipidus | |
Polymyxin B. Sulphate Injection... | Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Polyoestradiol Phosphate........ | Carcinoma of the prostate | |
Prednisolone Sodium Phosphate Retention Enema and Suppository | With the written authority of the Director-General— | |
Ulcerative colitis proven by sigmoidoscopy or radiological report | ||
| Proctitis proven by sigmoidoscopy | |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | |
Prednisolone Tablets, B.P........ | With the written authority of the Director-General— | |
| Nodular non-suppurative panniculitis (Christian-Weber disease) | |
| A disease or condition specified in this column in relation to Cortisone Injection except total adrenalectomy, Addison’s disease or adrenocortical hypoplasia | |
| Cerebral tumors and cerebral oedema | |
Prednisolone Acetate Injection..... |
|
|
Prednisolone Methyl Acetate Injections |
|
|
Prednisolone Tertiary Butyl Acetate Injections |
| Intra-articular use |
Prednisolone Trimethylacetate Injections |
|
|
Methylprednisolone Tablets, B.P.... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets except cerebral tumors and cerebral oedema | |
Methylprednisolone Capsules..... | ||
| ||
| ||
Prednisolone Sodium Hemisuccinate | With the written authority of the Director-General, medical or surgical crises | |
Prednisone Tablets, B.P.......... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets | |
Progesterone................ |
| |
| ||
Propranolol Hydrochloride....... | Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Pyrazinamide................ | ||
Pyridostigmine Injection, B.P...... |
| |
Pyridostigmine Tablets, B.P....... | ||
Pyridoxine Hydrochloride Tablets | Peripheral neuritis due to isoniazid therapy | |
| Radiation sickness | |
Quinine Bisulphate Tablets, B.P.... |
| |
Quinine Dihydrochloride Tablets... |
| |
Quinine Hydrochloride Tablets.... | Malaria | |
Quinine Sulphate Tablets, B.P..... |
| |
|
| |
Senna Fruit Extract (Standardised) | Any disease or condition in a pensioner | |
Sobee..................... | With the written authority of the Director-General— | |
| Galactosaemia | |
| Lactose intolerance | |
| Milk allergy in children under the age of four years | |
Sodium Aminosalicylate Tablets, B.P. |
| |
Sodium Aminosalicylate Injection | Tuberculosis | |
Sodium Aminosalicylate Cachets |
| |
Sodium Aminosalicylate Granules |
| |
Sodium Folate............... | Macrocytic anaemia | |
| Sprue or the sprue-like syndrome | |
Spiramycin................. | Serologically proven active toxoplasmosis | |
| Staphylococcal septicaemia or staphylococcal pneumonia | |
| Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins | |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | |
Spironolactone Tablets, B.P....... | With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate | |
Stanolone.................. | Mammary carcinoma | |
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | |
Stanozolol.................. | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | |
|
| Carcinoma of the prostate |
Stilboestrol Injection........... |
| Mammary carcinoma |
Stilboestrol Tablets, B.P......... |
| Any disease or condition in a pensioner |
|
| Hereditary Telangiectasis |
Streptomycin Sulphate Injections... | Bacillary dysentery that is resistant to the Sulphonamides | |
| Brucellosis | |
| Chancroid | |
| Endocarditis due to Streptococcus faecalis or Streptococcus viridans | |
| Friedlander bacillus infections | |
| Haemophilus influenzae infections | |
| Plague | |
| Pseudomonas pyocyanea infections | |
| Rat-bite fever (Streptobacillus moniliformis) | |
| Salmonella infections | |
| Surgical conditions of the bowel (pre-operative and post-operative) | |
| Surgical conditions of the thoracic organs | |
| Tuberculosis | |
| Tularaemia | |
| Urinary tract infections that are resistant to the Sulphonamides | |
Sulphasalazine............... | Ulcerative colitis | |
Sulphomyxin Sodium........... | Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Sultiame................... | For use where other anticonvulsants have failed | |
Surgical Cement.............. |
| |
Surgical Cement Solvent........ | Ileostomy or colostomy conditions | |
Sustanon................... |
| |
Testosterone Implants, B.P........ |
| |
Testosterone Oenanthate......... | Castration syndrome (male) | |
Testosterone Propionate Injection, B.P. | Klinfelter Reifenstein Albright syndrome | |
Mammary carcinoma | ||
Methyltestosterone Tablets, B.P.... |
| |
Methyltestosterone, B.P.......... |
| |
Tetanus Immune Globulin (Human) | With the written authority of the Director-General, where patients are known to be sensitive to horse serum and cattle serum | |
Tetracycline Capsules, B.P........ |
| |
Tetracycline Tablets, B.P......... |
| |
Tetracycline Injections.......... | A disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus | |
Rolitetracycline............... | ||
Tetracycline Hydrochloride Granules, Paediatric Drops and Syrup | ||
Tetracycline with a buffering agent |
| |
Tetracycline with a buffering agent and Amphotericin B |
| |
Tetracycline with a buffering agent and Nystatin | ||
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Thiambutosine Tablets, B.P....... | Hansen’s disease |
Thiethylperazine Tablets and Suppositories | With the written authority of the Director-General— |
Radiation sickness | |
|
|
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General— |
| Late-stage malignancy |
| Radiation sickness |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
Thioridazine Tablets, B.P......... | |
Thioridazine................. | |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride, Imipramine Hydrochloride or Nortriptyline Hydrochloride |
Thyrotrophin................ | Any disease in or condition in a patient receiving treatment in or at an approved hospital |
Tragacanth, Indian (Gum Karaya) | Ileostomy or colostomy conditions |
Trasylol.................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Tretamine................... | Malignant lymphoma and related conditions |
Triamcinolone................ | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets except cerebral tumors and cerebral oedema |
|
|
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General— |
| Late-stage malignancy |
| Radiation sickness |
Trifluoperazine Tablets, B.P....... | With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
Trifluoperazine Hydrochloride, B.P. | |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride, Imipramine Hydrochloride or Nortriptyline Hydrochloride |
Trimetaphan Injection, B.P........ | Hypotensive for anaesthesia |
Vadrine.................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Vasopressin Nasal Spray ........ | Diabetes insipidus |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act | |
Velactin.................... | With the written authority of the Director-General— | |
| Galactosaemia | |
| Lactose intolerance | |
| Milk allergy in children under the age of four years | |
Vinblastine Sulphate........... | Hodgkin’s disease | |
Vincristine Sulphate............ | Any disease or condition in a patient receiving treatment in or at an approved hospital | |
Viomycin Sulphate............ |
| |
Viomycin Sulphate Injection, B.P. | Tuberculosis | |
Viomycin Sulphate with Viomycin Pantothenate |
| |
Vitamin A with Aneurine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D |
| Any disease or condition in a pensioner |
_________________
By Authority: A.J. Arthur Commonwealth Printer, Canberra